Newswise — La Jolla, Calif., December 11, 2017 – Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex (LUBAC), regulating NFκB and other inflammatory molecules, SHARPIN modulates PRMT5, an epigenetic master switch that controls several proteins linked to melanoma. The research was published in The Journal of Clinical Investigation.
“More studies are showing how important PRMT5 is in cancer, and our research highlights another layer of regulation of this very important enzyme,” says Ze’ev Ronai, Ph.D., professor in the Tumor Initiation and Maintenance Program at SBP’s NCI-designated Cancer Center and senior author on the paper. “This shows the complexity of PRMT5 regulation and points to a new direction in targeting PRMT5.”
SHARPIN, is best known for its role in LUBAC, which plays a direct role in inflammatory signaling. However, SHARPIN has a second life, regulating PRMT5, which methylates individual genes and the histones that package DNA, controlling a wide range of gene expression. PRMT5 has been linked to prostate, breast, lung and other cancers.
Using human melanoma cell lines, the researchers found that SHARPIN (but not fellow LUBAC proteins HOIP and HOIL-1L) increases PRMT5 activity, which boosts transcription factors SOX10, PAX3 and MITF, all of which contribute to melanoma growth.
The researchers believe SHARPIN fine-tunes PRMT5, affecting how the enzyme methylates certain proteins, but not histones.
“SHARPIN actually dictates PRMT5 activity in a way we didn’t expect,” says Ronai. “It serves as a navigator, showing PRMT5 where to go and thus which proteins to methylate.”
SHARPIN becomes especially important in tumors that have lost proteins CDKN2A and MTAP, which are co-deleted in around 15 percent of all cancers. When MTAP is deleted, PRMT5 activity is reduced. However, in those cases SHARPIN acts as a counterbalance, boosting PRMT5. Epidemiological data show that patients whose tumors lack MTAP, and have elevated levels of SHARPIN, have poorer prognosis.
“Inhibiting SHARPIN in these tumor cells makes them much more susceptible to death,” says Hyungsoo Kim,P.D., who co-led the study.
Pharmaceutical companies have been racing to develop anti-PRMT5 drugs, but these findings underscore the complexity of the pathway. It’s quite possible that PRMT5 inhibitors and SHARPIN could end up in a tug of war, and SHARPIN inhibitors may be necessary to boost overall effectiveness.
“We may need to consider a possible combination of therapies,” adds Ronai. “PRMT5 inhibition by itself may not be sufficient, and we may thus want to consider combination therapies to achieve more complete inhibition.”
Co-authors of this collaborative study which spans the Technion in Israel and Shantou University in China include: Hironari Tamiya, Hyungsoo Kim, Heejung Kim, Yongmei Feng, Ji Yun Han, Ayako Murao, Scott J. Snipas, SBP; Oleksiy Klymenko, Technion Israel Institute of Technology; Tongwu Zhang, Kevin Brown, National Cancer Institute; Lucia Jilaveanu, Harriet Kluger, Yale University; Hao Zhang, Shantou University Medical College; and Kazuhiro Iwai, Kyoto University.
This study funded, in part, by NCI grants R21CA198468 and R35CA197465, and the Shantou University-Technion Reseach Program.
Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children’s diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.
MEDIA CONTACTRegister for reporter access to contact details
Journal of Clinical Investigation; R21CA198468; R35CA197465